Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma

Cancer

Volumn 118, Issue 22, 2012, Pages 5560-5571

  Hui, Bo ^a,b   Shi, Ying Hong ^a   Ding, Zhen Bin ^a   Zhou, Jian ^a   Gu, Cheng Yu ^a   Peng, Yuan Fei ^a   Yang, Hua ^a   Liu, Wei Ren ^a   Shi, Guo Ming ^a   Fan, Jia ^a  

^a FUDAN UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

apoptosis; autophagy; hepatocellular carcinoma; proliferation; proteasome

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CARBOBENZOXYVALYLALANYLASPARTYL(O METHYL)FLUOROMETHYKETONE; CASPASE INHIBITOR; CHLOROQUINE; DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; DNA NUCLEOTIDYLEXOTRANSFERASE; GREEN FLUORESCENT PROTEIN; KI 67 ANTIGEN; LIPOCORTIN 5; PROPIDIUM IODIDE; PROTEASOME; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER INHIBITION; CANCER THERAPY; CELL DENSITY; CELL PROLIFERATION; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; DRUG POTENTIATION; DRUG TARGETING; ELECTRON MICROSCOPY; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MONOTHERAPY; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; STAINING; TREATMENT OUTCOME; TUMOR MODEL; TUMOR VOLUME;

ADENINE; AMINO ACID CHLOROMETHYL KETONES; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; BORONIC ACIDS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CHLOROQUINE; CYSTEINE PROTEINASE INHIBITORS; HUMANS; LEUPEPTINS; MEMBRANE PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PYRAZINES;

EID: 84868203239     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27586     Document Type: Article

References (28)

1. El-Serag HB, Rudolph KL,. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132: 2557-2576.
2. Ruggero D,. The role of Myc-induced protein synthesis in cancer. Cancer Res. 2009; 69: 8839-8843.
3. Sorokin AV, Kim ER, Ovchinnikov LP,. Proteasome system of protein degradation and processing. Biochemistry (Mosc). 2009; 74: 1411-1442.
4. Ludwig H, Khayat D, Giaccone G, Facon T,. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer. 2005; 104: 1794-1807.
5. Henry L, Lavabre-Bertrand T, Vercambre L, et al. Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis. Gut. 2009; 58: 833-838.
6. Calvisi DF, Ladu S, Pinna F, et al. SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis [serial online]. Gastroenterology. 2009; 137: 1816e1-1826e10.
7. Ieta K, Ojima E, Tanaka F, et al. Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression. Int J Cancer. 2007; 121: 33-38.
8. Marino G, Lopez-Otin C,. Autophagy: molecular mechanisms, physiological functions and relevance in human pathology. Cell Mol Life Sci. 2004; 61: 1439-1454.
9. Chen S, Rehman SK, Zhang W, Wen A, Yao L, Zhang J,. Autophagy is a therapeutic target in anticancer drug resistance. Biochim Biophys Acta. 2010; 1806: 220-229.
10. Ding ZB, Hui B, Shi YH, et al. Autophagy activation in hepatocellular carcinoma contributes to the tolerance of oxaliplatin via reactive oxygen species modulation. Clin Cancer Res. 2011; 17: 6229-6238.
11. Shi YH, Ding ZB, Zhou J, et al. Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. Autophagy. 2011; 7: 1159-1172.
12. Dalby KN, Tekedereli I, Lopez-Berestein G, Ozpolat B,. Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy. 2010; 6: 322-329.
13. Igney FH, Krammer PH,. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002; 2: 277-288.
14. Ciechanover A,. Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Exp Biol Med (Maywood). 2006; 231: 1197-1211.
15. Wang X, Ottosson A, Ji C, et al. Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity. Haematologica. 2009; 94: 470-478.
16. Wang Y, Rishi AK, Puliyappadamba VT, et al. Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines. Cancer Chemother Pharmacol. 2010; 66: 455-466.
17. McConkey DJ, Zhu K,. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat. 2008; 11: 164-179.
18. Marten A, Zeiss N, Serba S, Mehrle S, von Lilienfeld-Toal M, Schmidt J,. Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma. Mol Cancer Ther. 2008; 7: 3624-3631.
19. Williamson MJ, Silva MD, Terkelsen J, et al. The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models. Mol Cancer Ther. 2009; 8: 3234-3243.
20. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999; 59: 2615-2622.
21. Kirkin V, McEwan DG, Novak I, Dikic I,. A role for ubiquitin in selective autophagy. Mol Cell. 2009; 34: 259-269.
22. Gao Z, Gammoh N, Wong PM, Erdjument-Bromage H, Tempst P, Jiang X,. Processing of autophagic protein LC3 by the 20S proteasome. Autophagy. 2010; 6: 126-137.
23. Verfaillie T, Salazar M, Velasco G, Agostinis P,. Linking ER stress to autophagy: potential implications for cancer therapy [serial online]. Int J Cell Biol 2010: 930509, 2010.
24. Yorimitsu T, Nair U, Yang Z, Klionsky DJ,. Endoplasmic reticulum stress triggers autophagy. J Biol Chem. 2006; 281: 30299-30304.
25. Bjorkoy G, Lamark T, Pankiv S, Overvatn A, Brech A, Johansen T,. Monitoring autophagic degradation of p62/SQSTM1. Methods Enzymol. 2009; 452: 181-197.
26. Levine B, Yuan J,. Autophagy in cell death: an innocent convict? J Clin Invest. 2005; 115: 2679-2688.
27. Wright JJ,. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin Cancer Res. 2010; 16: 4094-4104.
28. Milano A, Perri F, Caponigro F,. The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib. Onco Targets Ther. 2009; 2: 171-178.